Hese patients (n = 58). In this Cohort of CaP patients, association of PSA with progression of CaP was also observed (r = 0.57, p,0.001, Fig. 4C). The serum PSA level for each patient is provided in Table 2. BMI1 was modestly correlated with PSA (r = 0.58, p,0.001, Fig. 4D). BMI1 4 IBP site remained significantly (p,0.001) when adjusting for PSA in a regression model predicting cancer stage group.BMI1:Potential Serum-Biomarker for Prostate Cancer` Table 2. Comparative analysis of serum-PSA and serum-BMI1 in prostate cancer patients vis-a-vis Gleason score.Therapy S.N. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Age 78 57 66 70 65 80 78 57 66 70 73 73 83 74 70 82 72 72 81 57 60 64 75 47 58 63 72 78 67 73 77 69 70 73 65 68 70 60 54 65 57 69 85 52 68 80 57 76 Stages II II II II II II II II II II II II II II II II III III III III III III III III III III III III III III III IV IV IV IV IV IV IV GS 3+3 3+3 3+3 3+3 3+3 3+3 3+3 3+2 3+3 3+3 3+3 3+3 4+3 3+3 3+3 3+3 3+4 4+3 3+3 3+4 4+4 4+3 3+4 3+3 4+3 3+4 3+4 3+4 3+4 4+3 4+3 3+3 4+4 9+0 3+4 4+4 6+4 3+3 DA 71 51 77 73 57 79 71 51 77 57 60 60 75 47 58 63 66 77 62 67 73 64 66 77 62 66 69 60 54 65 57 66 80 51 64 76 53 65 MS N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N Li, L N N Li N CT N N Y N N N N N Y N N N N N Y N N N N N N N N N N N N N N N Y N N Y N N Y Y Y Y N Y Y Y N Y Y N N N N N N N Y N Y Y N Y Y N Y N N Y N N N N N Y Y Y N N RT HT N Y Y N Y Y Y N Y N N Y N N Y N Y Y N Y Y Y Y Y N Y Y N N N Y Y Y Y Y Y Y Y Serum collected during Remission Treatment Treatment Treatment Remission Treatment Remission Treatment Treatment Detection Detection Treatment Detection Detection Treatment Detection Remission Treatment Remission Remission Treatment Remission Remission Treatment Remission Treatment Treatment Treatment Detection Detection Treatment Remission Treatment Treatment Remission Treatment Treatment Treatment CaP Type AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC ACng/ml serum PSA 1.18 2.8 4.43 3.63 2.01 2.02 0.29 2.45 2.72 4.51 10.38 11.27 2.51 13.51 1.48 13.39 BMI1 0.81 3.2 2.32 3.09 0.97 0.97 0.94 1.02 2.37 1.46 3.83 4.39 10.96 4.24 3.72 4.0.6.62 10.56 1.91 4.62 3.75 2.72 14.45 19.91 25.33 13.04 35.87 7.02 3.30 20.06 23.16 21.83 33.35 12.29 6.45 7.70 12.72 23.18 13.54 18.08 35.96 57.67 32.07 57.64 74.57 67.97 89.2.3.04 2.24 7.80 2.37 2.61 1.37 2.89 2.35 3.67 5.26 17.52 15.49 13.23 15.30 9.39 10.01 6.79 7.95 4.56 4.37 3.86 7.51 3.83 3.13 14.02 17.69 12.21 14.29 16.34 5.59 4.BMI1:Potential Serum-Biomarker for Prostate CancerTable 2. Cont.Therapy S.N. 49 50 51 52 53 54 55 56 57 58 Age 74 73 70 47 60 59 72 63 75 75 Stages IV IV IV IV IV IV IV IV IV IV GS 2+1 6+2 4+5 4+4 4+5 3+5 4+5 5+4 4+3 4+4 DA 74 62 70 46 15826876 60 59 72 63 73 64 MS B B, L N N N N N N N N CT N N N Y N N N N N N RT Y Y N N N N N N Y N HT Y Y N Y N N N N N Y Serum collected during Treatment Treatment Treatment Treatment Detection Detection Detection Detection Treatment Treatment CaP Type AC AC AC AC AC AC AC AC AC ACng/ml serum PSA 25.91 17.27 71.32 6.78 BMI1 6.71 13.23 24.89 14.0.11.0 13.16 4.02 10.35 71.3.6.58 4.79 5.39 6.30 14.N Eliglustat web represents NO; Y represents Yes; AC represents adenocarcinoma; CaP represents prostate cancer; GS represents Gleason score; DA represents diagnosis age; MS represents metastatic site; CT represents chemotherapy; RT represents radiation therapy, HT re.Hese patients (n = 58). In this Cohort of CaP patients, association of PSA with progression of CaP was also observed (r = 0.57, p,0.001, Fig. 4C). The serum PSA level for each patient is provided in Table 2. BMI1 was modestly correlated with PSA (r = 0.58, p,0.001, Fig. 4D). BMI1 remained significantly (p,0.001) when adjusting for PSA in a regression model predicting cancer stage group.BMI1:Potential Serum-Biomarker for Prostate Cancer` Table 2. Comparative analysis of serum-PSA and serum-BMI1 in prostate cancer patients vis-a-vis Gleason score.Therapy S.N. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Age 78 57 66 70 65 80 78 57 66 70 73 73 83 74 70 82 72 72 81 57 60 64 75 47 58 63 72 78 67 73 77 69 70 73 65 68 70 60 54 65 57 69 85 52 68 80 57 76 Stages II II II II II II II II II II II II II II II II III III III III III III III III III III III III III III III IV IV IV IV IV IV IV GS 3+3 3+3 3+3 3+3 3+3 3+3 3+3 3+2 3+3 3+3 3+3 3+3 4+3 3+3 3+3 3+3 3+4 4+3 3+3 3+4 4+4 4+3 3+4 3+3 4+3 3+4 3+4 3+4 3+4 4+3 4+3 3+3 4+4 9+0 3+4 4+4 6+4 3+3 DA 71 51 77 73 57 79 71 51 77 57 60 60 75 47 58 63 66 77 62 67 73 64 66 77 62 66 69 60 54 65 57 66 80 51 64 76 53 65 MS N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N Li, L N N Li N CT N N Y N N N N N Y N N N N N Y N N N N N N N N N N N N N N N Y N N Y N N Y Y Y Y N Y Y Y N Y Y N N N N N N N Y N Y Y N Y Y N Y N N Y N N N N N Y Y Y N N RT HT N Y Y N Y Y Y N Y N N Y N N Y N Y Y N Y Y Y Y Y N Y Y N N N Y Y Y Y Y Y Y Y Serum collected during Remission Treatment Treatment Treatment Remission Treatment Remission Treatment Treatment Detection Detection Treatment Detection Detection Treatment Detection Remission Treatment Remission Remission Treatment Remission Remission Treatment Remission Treatment Treatment Treatment Detection Detection Treatment Remission Treatment Treatment Remission Treatment Treatment Treatment CaP Type AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC ACng/ml serum PSA 1.18 2.8 4.43 3.63 2.01 2.02 0.29 2.45 2.72 4.51 10.38 11.27 2.51 13.51 1.48 13.39 BMI1 0.81 3.2 2.32 3.09 0.97 0.97 0.94 1.02 2.37 1.46 3.83 4.39 10.96 4.24 3.72 4.0.6.62 10.56 1.91 4.62 3.75 2.72 14.45 19.91 25.33 13.04 35.87 7.02 3.30 20.06 23.16 21.83 33.35 12.29 6.45 7.70 12.72 23.18 13.54 18.08 35.96 57.67 32.07 57.64 74.57 67.97 89.2.3.04 2.24 7.80 2.37 2.61 1.37 2.89 2.35 3.67 5.26 17.52 15.49 13.23 15.30 9.39 10.01 6.79 7.95 4.56 4.37 3.86 7.51 3.83 3.13 14.02 17.69 12.21 14.29 16.34 5.59 4.BMI1:Potential Serum-Biomarker for Prostate CancerTable 2. Cont.Therapy S.N. 49 50 51 52 53 54 55 56 57 58 Age 74 73 70 47 60 59 72 63 75 75 Stages IV IV IV IV IV IV IV IV IV IV GS 2+1 6+2 4+5 4+4 4+5 3+5 4+5 5+4 4+3 4+4 DA 74 62 70 46 15826876 60 59 72 63 73 64 MS B B, L N N N N N N N N CT N N N Y N N N N N N RT Y Y N N N N N N Y N HT Y Y N Y N N N N N Y Serum collected during Treatment Treatment Treatment Treatment Detection Detection Detection Detection Treatment Treatment CaP Type AC AC AC AC AC AC AC AC AC ACng/ml serum PSA 25.91 17.27 71.32 6.78 BMI1 6.71 13.23 24.89 14.0.11.0 13.16 4.02 10.35 71.3.6.58 4.79 5.39 6.30 14.N represents NO; Y represents Yes; AC represents adenocarcinoma; CaP represents prostate cancer; GS represents Gleason score; DA represents diagnosis age; MS represents metastatic site; CT represents chemotherapy; RT represents radiation therapy, HT re.
http://calcium-channel.com
Calcium Channel
